68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: Comparison with 18F-FDG

Journal of Nuclear Medicine

Volumn 48, Issue 8, 2007, Pages 1245-1250

  Dimitrakopoulou Strauss, Antonia ^a   Hohenberger, Peter ^b   Haberkorn, Uwe ^a,b   Mäcke, Helmut R ^c   Eisenhut, Michael ^a   Strauss, Ludwig G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

18F FDG; 68Ga bombesin; GIST; Kinetic modeling; PET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; BOMBESIN DERIVATIVE; BOMBESIN DERIVATIVE GA 68; ETHYLENE GLYCOL DERIVATIVE; FLUORODEOXYGLUCOSE F 18; GALLIUM 68; IMATINIB; UNCLASSIFIED DRUG; BOMBESIN; DIAGNOSTIC AGENT; GALLIUM; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DRUG UPTAKE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; INOPERABLE CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; RADIOGRAPHY; SCINTISCANNING; STATISTICAL MODEL;

BOMBESIN; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LINEAR MODELS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34547770763     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.038091     Document Type: Article

References (20)

1. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
2. 90Y-90-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2005;33:460-466.
3. Reubi JC, Körner M, Waser B, Mazzucchelli L, Guillou L. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours. Eur J Nucl Med Mol Imaging. 2004;31:803-810.
4. 68Ga-labeled bombesin (6-14) analog. J Nucl Med. 2005;46:691-699.
5. 18F)fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Int J Rad Appl Instrum B. 1990;17:273-279.
6. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623-648.
7. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818-1823.
8. Mikolajczyk K, Szabatin M, Rudnicki P, Grodzki M, Burger C. A Java environment for medical image data analysis: initial application for brain PET quantitation. Med Inform (Lond). 1998;23:207-214.
9. 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263-272.
10. Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L, eds. The Metabolism of the Human Brain Studied with Positron Emission Tomography. New York, NY: Raven Press; 1983:123-148.
11. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432-1438.
12. Dimitrakopoulou-Strauss A, Strauss LG, Mikolajczyk K, et al. On the fractal nature of dynamic positron emission tomography (PET) studies. World J Nucl Med. 2003;2:306-313.
13. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-2020.
14. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-162.
15. 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:823-830.
16. 18F-Labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med. 2006;47:492-501.
17. 68Ga-DOTA-D-PHE1-TYR3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46:763-769.
18. 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging. 2006;33:1115-1122.
19. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34:414-429.
20. 18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med. 2004;45:1528-1535.